Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05796570 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05796570 · ClinicalTrials.gov record · last posted 2026-08-20

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

Study acronym: MORE
StatusActive, Not Recruiting
PhasePhase 2
Started2023-04-19
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to examine if it is feasible to administer decitabine and filgrastim after allogenic hematopoietic stem cell transplant (HCT) in children and young adults with myelodysplastic syndrome, acute myeloid leukemia and related myeloid disorders, and if the treatment is effective in preventing relapse after HCT. The names of the study drugs involved in this study are: * Decitabine (a nucleoside metabolic inhibitor) * Filgrastim (a recombinant granulocyte colony-stimulating factor (G-CSF)

Protocol amendment history 2 changes detected by DataLookout

2026-08-21
Enrollment closed, study ongoing
2026-08-21
Enrollment reduced: 37 → 29 participants
Trial Details
NCT Number NCT05796570
Lead Sponsor Franziska Wachter
Collaborators: Harvard Clinical and Translational Science Center (Harvard Catalyst)
Conditions Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies, MDS, Inherited Bone Marrow Failure Syndrome, Myeloid Neoplasm, Aml
Enrollment 29 participants
Start Date 2023-04-19
Primary Completion 2026-08-19 (estimated)
Study Completion 2029-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-20